COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-2 will be US$ [**], made up of: - Manufacture and supply of 2 GMP batches US $ [**] ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. - Process analysis US $ [**] - Short term stability study (2.2.3) US $ [**] - (transferred from Section 2.2.2 of Schedule B-1) Payments will be made to Abbott by Barrier as follows: - [**] - [**] - [**] - [**] - [**] ABBOTT GMBH & CO. KG BARRIER THERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Geert Cauwenbergh ---------------------------------- ---------------------------------- Dr. Jorg Breitenbach Head of SOLIQS By: /s/ Jon Lewis Xxxe: 30 September 2002 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 27 Xxxxxxxxx 2002 -------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-3 WORKPLAN FOR STAGE 3
COSTS AND PAYMENT SCHEDULE. In consideration for ICON’s Services under this Project Contract, NTI agrees to pay ICON in accordance with the budget set forth in the attached Exhibit B and incorporated herein by reference. The total amount payable by NTI to ICON in respect of direct fees, exclusive of pass-through expenses, under this Project Contract shall in no way exceed [***] without prior written consent of both parties. Pass-through expenses under this Project Contract are estimated to be [***].
COSTS AND PAYMENT SCHEDULE. In consideration for ICON’s Services under this Project Contract, NTI agrees to pay ICON in accordance with the budget set forth in the attached Exhibit B and incorporated herein by reference. The total amount payable by NTI to ICON in respect of direct fees, exclusive of pass-through expenses, under this Project Contract shall in no way exceed Six Hundred Five Thousand One Hundred Ninety-Four dollars ($605,194) without prior written consent of both parties. Pass-through expenses under this Project Contract are estimated to be Four Thousand Two Hundred and Fifty dollars ($4,250).
COSTS AND PAYMENT SCHEDULE. In consideration of the Project performed by Enumeral, Novartis agrees to pay to Enumeral a fee in the amount of * according to the payment schedule outlined below plus VAT if applicable. Payment schedule: Services Milestone Deliverable Deliverable due date Payment $50,000 up front Assay design and testing #1 Novartis approval of interim data report Interim data report with results from * * * Assessment of * profiles under multiple stimulation conditions #2 Novartis approval of final report Final Report detailing the results of the * * * *
COSTS AND PAYMENT SCHEDULE. In consideration of the proper performance of the Study by the Institution and the Principal Investigator under the terms of this Agreement and upon approval of Sponsor, payment will be made by Medpace or its designee to the payee (“Payee”) designated in Schedule A-Institution and in Schedule A-Principal Investigator appended hereto and incorporated herein by reference. Institution and Principal Investigator will accept payment from Medpace, or its designee, to the Payee as full consideration for services rendered. All costs outlined on Schedule A-Institution / Schedule A-Principal Investigator shall remain firm for the duration of the Study, unless otherwise agreed to in writing by the Institution and Medpace. It is understood and agreed that no reimbursement will be provided by Medpace or Sponsor for subjects who are randomized into the Study in violation of the Protocol, or who do not conform to the Protocol’s inclusion and exclusion criteria or for whom serious deviations from the Protocol are made. The budget contained in Schedule A-Institution / Schedule A-Principal Investigator is inclusive of all applicable taxes. VAT is not applicable because Medpace is a U.S.-based company. Should any changes to VAT law occur during the term of this Agreement or other tax laws require withholding, the party legally responsible shall be liable for VAT or withholdings. Insert for non- EU countries: Should any tax laws require withholding, the party legally responsible shall be liable for withholdings. Medpace, as Sponsor’s payment agent, shall make payment to Payee under this Agreement from funds provided by Sponsor. Notwithstanding the foregoing, Medpace may issue a written amendment, signed only by Medpace, for the purpose of increasing the Study costs as described in the Schedule A-Institution / Schedule A-Principal Investigator. 6
COSTS AND PAYMENT SCHEDULE. In consideration of the proper performance of the Study by the The Health Services Provider and the Principal Investigator under the terms of this Agreement, payment will be made by Medpace or its designee to the payee (“Payee”) designated in Schedule A appended hereto and incorporated herein by reference. The Health Services Provider will accept payment from Medpace, or its designee, to the Payee as full consideration for services rendered. All costs outlined on Schedule A shall remain firm for 6 NÁKLADY A ROZVRH PLATEB Jako odměna v souvislosti s řádným prováděním studie ze strany poskytovatele zdravotních služeb a hlavního zkoušejícího podle podmínek této smlouvy bude společností Medpace nebo jejím pověřeným zástupcem provedena úhrada příjemci platby (xxxx xxx „příjemce platby“) označenému v příloze A připojené k této smlouvě a začleněné do ní odkazem. Poskytovatel zdravotních služeb přijme platbu od společnosti Medpace, nebo jejího zástupce, jako plnou úhradu za poskytnuté služby. Všechny náklady
COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-5 will be [**] made up of: [**] Payments will be made by Barrier to Abbott as follows: [**] ** Certain information in this exhibit hax xxxx omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ABBOTT GMBH & CO. KG BARRIER THERAPEUTIXX, XXC. By: ppa /s/ Jorg Breitenbach By: /s/ Charles T. Nomides ---------------------------------- ------------------------ Dr. Jorg Breitenbach Director, Head of SOLIQS
COSTS AND PAYMENT SCHEDULE. A. All costs and rates outlined in a Work Order shall remain firm for the duration of the Work Order, unless otherwise agreed to in writing by CLINIMETRICS and CLIENT.
COSTS AND PAYMENT SCHEDULE. Abbott's costs for carrying out the programme of work set out in thix Xxxxxxle B-3 will be US$ [**] make up of: - Manufacture and supply of manufacture [**] kg Bulk Product US $ [**] - Process analysis US $ [**] Payments will be made to Abbott by Barrier as follows: - US$[**] within 30 days of signature of this Schedule B-3, - US$[**] on Barrier's receipt of the report. ABBOTT GMBH & CO. KG BARRIER THERAPEUTICS, INC. Xx: /s/ Jorg Breitenbach By: /s/ Charles T. Nomides ---------------------------------- ---------------------------------- Dr. Jorg Breitenbach Charles T. Nomides Xxxx xx XXXXXX XXX Xx: /x/ Xxx Xewis Date: 11-MAR-03 ---------------------------------- -------------------------------- Dr. Jon Lewis Head of Business Development SOLIQS Date: 18 Xxxxx 0003 --------------------------------- ** Certain information in this exhibit has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. ATTACHMENT TO DEVELOPMENT AND SUPPLY AGREEMENT BETWEEN ABBOTT GMBH & CO. KG AND BARRIER THERAPEUTICS, INC. SCHEDULE B-4 PRE-STAGE 5 WORKPLAN 1. AIM OF WORK Abbott will manufacture two batches of [**] kg Bulk Product to be used for technical and analytical assessment and further manufacturing trials. The target of these trials is to [**]. Analytical testing will be carried out with the intention of defining methods of distinguishing between different batches of Bulk Product. The technical responsibilities will be described hereinafter.
COSTS AND PAYMENT SCHEDULE. In consideration of Vendor’s performance of the Data Reporting Services hereunder, ARIAD shall pay Vendor the Service Fees as set forth below. Vendor shall submit monthly invoices to ARIAD not later than thirty (30) calendar days after the end of each calendar month. Vendor’s invoices must be accompanied by adequate supporting documentation for all amounts requested, as well as any other terms or information as reasonably requested by ARIAD. Invoices shall be due and payable within thirty (30) calendar days after ARIAD’s receipt of such properly supported invoices; provided, however, that ARIAD may contest any invoice or portion thereof, to the extent that it reasonably believes that the charges reflected therein are inappropriate or lack a clear basis (paying all charges that are appropriate). Once any such issue or concern is resolved, ARIAD shall pay any remaining appropriate charges within thirty (30) calendar days of the date that such resolution occurs. Data Reporting Services Fee $[***] per each prescription dispensed Data Reporting Services Fee: The Data Reporting Services Fee will be paid based on daily referral status/shipment report transmitted by the Vendor to the Daily Aggregator (as set forth below in Report # 1). The Data Reporting Services Fee will also be paid based on monthly 852 data transmitted by the Vendor to the Data Aggregator (as set forth below in Report #2). ARIAD reserves the right to quarterly written confirmation of Vendor’s monthly 852 inventory file. To evidence the Parties’ agreement to this SOW, they have signed and delivered it as of the last date written below. CONFIDENTIAL – DO NOT COPY Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. ARIAD Pharmaceuticals, Inc. Biologics, Inc. By: /s/ Xxxxx X. Xxxxxx By: /s/ Xxxxxx Xxxxx Name: Xxxxx X. Xxxxxx Name: Xxxxxx Xxxxx Title: SVP, Commercial Operations Title: Chief Business Development Officer Date: 1/14/14 Date: 1/14/14 CONFIDENTIAL – DO NOT COPY Portions of this Exhibit, indicated by the xxxx “[***],” were omitted and have been filed separately with the Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended...
